The Role of Percutaneous Ventricular Restoration Therapy in Heart Failure After Myocardial Infarction
DOI:
https://doi.org/10.37275/bsm.v6i2.440Keywords:
Myocardium, Myocardial infarction, Restoration therapy, Heart failure, Percutaneous ventricleAbstract
The process of ventricular remodeling has a major role in the pathogenesis of heart failure in patients with myocardial infarction. Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), antialdosterone diuretics, and beta receptor blockers are drugs that have been widely accepted as anti-remodeling agents. However, sometimes the efficacy of these drugs is inadequate, or their use is constrained by low blood pressure. Percutaneous ventricular restoration therapy is an action that aims to exclude segments of the myocardium that have akinetic or aneurysms by implanting a ventricular partitioning device percutaneously. This technique is expected to prevent the progression of ventricular remodeling through a procedure with a lower risk of intraprocedural mortality than the surgical approach.
Authors
- Yudhie Tanta1*
- Ali Ghanie2
- Taufik Indrajaya2
- Erwin Sukandi2
- 1Subspecialized Residency Training, Division of Cardiovascular, Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya/ Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia
- 2Division of Cardiovascular, Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya/ Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia
Corresponding author Yudhie Tanta — tanta7an7a@yahoo.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
